Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
28 November 2023 - 11:30PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that Troy Wilson, Ph.D., J.D., President and Chief Executive
Officer, is scheduled to participate in a virtual fireside chat at
the JMP Securities Hematology and Oncology Summit at 2:00 p.m. ET /
11:00 a.m. PT on Tuesday, December 5, 2023.
A live audio webcast of the presentation will be
available in the Investors section of Kura’s website at
www.kuraoncology.com, with a replay available shortly after the
live event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical
company committed to realizing the promise of precision medicines
for the treatment of cancer. The Company’s pipeline consists of
small molecule drug candidates that target cancer signaling
pathways. Ziftomenib is a once-daily, oral drug candidate targeting
the menin-KMT2A protein-protein interaction for the treatment of
genetically defined acute myeloid leukemia (AML) patients with high
unmet need. Kura is currently enrolling patients in a Phase 2
registration-directed trial of ziftomenib in NPM1-mutant relapsed
or refractory AML (KOMET-001). The Company is also conducting a
series of studies to evaluate ziftomenib in combination with
current standards of care, beginning with venetoclax/azacitidine
and standard induction cytarabine/daunorubicin chemotherapy in
NPM1-mutant and KMT2A-rearranged newly diagnosed and
relapsed/refractory AML (KOMET-007). Tipifarnib, a potent and
selective FTI, is currently in a Phase 1/2 trial in combination
with alpelisib for patients with PIK3CA-dependent head and neck
squamous cell carcinoma (KURRENT-HN). Kura is also evaluating
KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial
as a monotherapy and in combination with other targeted therapies
(FIT-001). For additional information, please visit Kura’s website
at www.kuraoncology.com and follow us on X and LinkedIn.
Contacts
Investors:Pete De SpainExecutive Vice President,
Investor Relations &Corporate Communications(858)
500-8833pete@kuraoncology.com
Media:Alexandra WeingartenSenior Manager, Corporate
Communications(858) 500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024